better breast implant market ripe
innov initi buy pt
motiva implant esta reimagin breast augment
clinic outcom prove better anyth seen
esta launch motiva countri us trial underway
approv model revenu compound-annual-growth-rate next year
clinic data continu good earli result
opportun esta grow well beyond signific pt
better implant attract market esta found sole purpos
develop silicon breast implant improv safeti aesthet outcom
compani reimagin everi aspect implant motiva offer produc
product show excel clinic result strong commerci
market want innov esta success mani way due much
innov lack innov part competitor evolut
silicon breast implant complex mark earli advanc larg stall
safeti concern ultim high regulatori burden last meaning chang
year ago introduct highli cohes silicon clinic improv
also stall best implant competitor still show rate reoper
year ruptur capsular contractur despit result
market opportun still signific global ou
us grow mid-singl digit
impress earli result much come motiva earli result clinic
commerci impress sever data set motiva show overal
complic rate reoper rate lower implant esta
sale countri steadili gain shareesta enter brazil
second largest global market year ago alreadi approach share
market esta share major catalyst us fda trial underway
expect fulli enrol earli fda studi data mirror exist data
motiva esta prime take even bigger portion us global market
buy rate price target better product market ripe take
model revenu compound-annual-growth-rate next five year place esta among best
med-tech stori price target ev/sal initi buy rate
jefferi joint book-run manag esta juli initi public offer
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
esta growth sustain
us market penetr market entri
continu market penetr ou asp increas due
region mix shift time
applic breast reconstruct
includ forecast
multipl sale price
esta one highest growth profil med-tech
esta target market less
penetr current market
geographi applic pipelin
data suggest implant qualiti competitor
match forese futur given amount time
taken esta come truli innov
esta growth exce remain
us market penetr meaning
market entri
continu market penetr ou asp increas due
continu penetr new geographi rate similar
preced countri
entri addit applic breast reconstruct
region mix shift time
contributor earlier expect
multipl sale price
esta growth slow
thereaft
us market penetr significantli
market entri delay market entri
continu market penetr ou asp
increas due region mix shift time
applic breast reconstruct
includ forecast
multipl sale price
page
pleas see import disclosur inform page report
establish lab medic devic compani focus breast implant found
compani oper sole purpos disrupt silicon
breast implant market creat product improv safeti aesthet outcom
implant trade name motiva began
commerci motiva implant avail countri includ
nine top global market establish lab sold close
motiva implant around world one except us compani
fda trial underway trial expect put compani onto us market
compani seen good earli success sale grow
model growth model
growth sever key underpin success
bode well continu strong result compani
first breast implant market seen littl innov past year
evolut silicon breast implant complex mark earli innov
larg stall safeti concern ultim high regulatori burden
current domin compani done littl advanc scienc product
clinic perform leav signific room improv best data
current gener implant year still show reoper rate ruptur
rate capsular contractur patient
second esta brought innov level breast implant
level implant develop novel technolog around
shell implant silicon gel shape implant
textur also includ small transpond implant
give identif inform overtim abl give
surgic procedur introduc brand surgeri
combin imag fat graft minim scare near-
term introduc surgeri call mint first breast
implant procedur done outpati basi without gener
market side aggress social media presenc hold
number physician educ engag event everi year
compani also integr tool call motivaimagin
center clinic brand build practic around full suit
lastli perhap importantli clinic data establish implant
promis much better anyth seen implant market data
motiva come three main sourc
retrospect studi implant publish sforza et al
aesthet surgeri journal septemb
post-market registri implant
on-going prospect follow-up clinic evalu patient
page
pleas see import disclosur inform page report
paper dr sforza promis set data far studi report
three-year perform consecut motiva implant singl center dolan
park hospit bromsgrov england group plastic surgeon main
take-away period late complic case primari
capsular contractur overal reoper rate even
intrigu though studi also includ anecdot analysi
surgeon year prior switch motiva period overal revis
rate group util differ macro-textur fda approv
implant believ allergan treatment protocol
order magnitud higher rate report motiva
chart motiva patient less like requir revis oper
sforza md et al evalu experi silksurfac
clinic studi thu far support show result
better anyth seen small mostli retrospect prospect
us fda trial gold standard implant judg establish
receiv approv start pma studi fda march first patient
enrol april trial studi compani expect
complet enrol earli two-year follow-up motiva us
market late earli compani releas one-year two-year
report data becom avail us trial
establish sell implant countri mix distributor direct
channel compani direct six market brazil uk franc sweden denmark
norway end sale direct sale
differ price distributor surgeon directli geograph market
also differ price make market size difficult sell price motiva
rang certain distribut latin american market approach
direct european market global million breast augment
procedur averag sell price yield market outsid us
us market procedur year higher
per implant market us current annual
give indic compani success thu far establish enter brazil
middl alreadi better dollar market share sever
market like scandinavia countri japan approach market
share overal compani achiev market share market outsid us
end
main driver growth near-term continu share captur exist
market increas price compani move direct market lastli
move new market outlook share captur well support
compani strong clinic data use advanc market proxi
page
pleas see import disclosur inform page report
increas realiz price also signific driver compani move direct
number market expect increas current
lastli compani target sever new market though motiva nine
top market alreadi less contributor entri us market
forecast revenu growth growth
compani enter us market late growth
expect acceler dramat model compani
revenu compound-annual-growth-rate model
chart esta annual revenu date forecast
compani data jefferi estim
compani manufactur implant two facil costa rica
capac produc implant per year process manufactur
implant fairli manual almost half cost implant silicon
establish buy sole supplier compani expect drive
signific underli gross margin expans though note move
direct sale eventu entri us market much higher
margin natur trend higher similarli compani expect invest
aggress sale market includ us clinic trial
come year leverag like meaning follow
ipo rais esta approxim cash debt
debt interest libor matur
model compani break-even cash burn stand point cash
hand suffici see compani good amount cushion
term valuat esta current trade revenu versu high growth
med-tech comp set trade publicli trade breast implant
compani trade howev imperfect comp
compani diversifi away breast implant recent acquisit energi
base aesthet platform disaggreg valuat energy-bas platform
like pull overal multipl base similar type stori trade
suggest breast like closer comp group trade use
sale esta yield current multipl roll forward discount
comp set yield initi one-year price target
beyond valuat buy rate support core idea esta develop
highli differenti demonstr better product market high barrier
entri seen littl innov year esta replic
earli clinic data larger rigor fda trial current underway
reason think wont compani prime take signific share
global market excess grow singl digit opportun
page
pleas see import disclosur inform page report
valu creation signific put context time esta captur
global implant market reason multipl matur
growth med-tech compani enterpris valu would share
price approach
compani major global market breast implant
market grow mid-singl digit share take main driver
growth forecast next five year market competit
esta much larger better resourc compani
clinic data set motiva compel still earli small
whether strong result shown thu far replic larger
rigor fda clinic trial close watch
time fda submiss approv could take longer expect
fda hard rule much data compani submit
approv whether two year enough assum question
breast implant-associ anaplast larg cell lymphoma bia-alcl still
rel rare occurr yet show signific impact implant
use howev condit becom preval gain
attent media could begin slow market accept breast
augment literatur suggest bia-alcl appear often
individu textured-breast implant smooth fill silicon salin
doesnt seem matter often thu far allergan implant
case alcl associ motiva implant
page
pleas see import disclosur inform page report
innov
evolut silicon breast implant complex mark earli innov
larg stall safeti concern ultim high regulatori burden
lack continu progress part incumb well high barrier entri
intens regulatori scrutini breast implant creat opportun
new entrant meaning innov captur signific market share
silicon breast implant develop corn implant
regul medic devic us silicon quickli becam gold
standard implant gave aesthet result significantli better
anyth previous avail howev earli report potenti link
implant connect tissu diseas began surfac defin
event develop silicon breast implant fda moratorium sale
implant us start sever countri follow fda lead
includ germani spain franc austria itali moratorium
on-going concern safeti well signific liabil number larg award
plaintiff sever larg manufactur includ origin withdrew
market never came back allergan mentor eventu abl
bring implant back market us follow enter market
moratorium sale implant neg affect
patient percept safeti implant also compani willing invest
main gener silicon breast implant introduc unit
state market last year implant saw sever increment chang
earli year includ differ surfac textur shape viscos silicon
littl real innov past year improv
clinic perform implant larg stall implant avail today
differ much origin thick silicon shell devic fill
silicon gel first launch
chart evolut silicon breast implant
adapt breast implant surfac develop perspect develop manufactur barr et al aesthet surgeri
page
pleas see import disclosur inform page report
innov focusperiod use surfacecoreshellsmooththin silicon mmthird generationfix issu thin shell bleed onwardsmooth thicker mmfourth gener textur focu shape improv onwardtextur salt-loss techniqu imprint moldingmanufacturer-specif gener mmtextured/smooth surfaceanatomically-shapedmanufacturer-specificlow bleedhighli cross-link onwardfifth gener cohes gel second generationfirst generationsoft natur feel implantsform shape stabl anatom shape highli cohes mmsmooth surfac dacron patch posteriorlyto anchor implantthick esta
earli period develop focus develop implant
natur feel second gener thin construct led silicon bleed
correct next gener third earli implant smooth textur
implant could move around within breast believ increas rate
implant ruptur capsular contractur address manufactur began add
textur implant offer fourth gener came form pebbl
rough surfac mimick sandpap creat enough friction prevent movement
implant also allow shape implant
last layer innov highly-cohes gel implant eventu
call gummi bear implant implant design retain shape
textur maintain posit innov gummi bear implant seem
origin concept highli cohes gel compani move
even highli cohes formul fda approv high-
strength cohes gel fill round shape devic textur surfac
mentor memoryshap allergan natrel form stabl shape
devic last major approv us market realli last
major chang implant technolog
chart histori silicon implant
clinic perform latest gener implant show still
signific opportun improv even best implant still show
reoper rate rang year ruptur rate capsular
contractur patient
chart clinic outcom current gener implant offer room
page
pleas see import disclosur inform page report
first report implant silicon gel implant cronin silicon implant manufactur dip coat lead high level capsular act breast implant includ class ii devic breast implant reclassifi class respons emerg safeti concern fda announc voluntari moratorium silicon gel-fil breast implant request surgeon stop suppli fda approv allergan adjunct studi protocol silicon gel-fil implant reconstruct revis fda approv allergan mentor silicon gel-fil implant applic condit post-approv studi conduct year fda approv mentor allergan pma silicon gel-fil implant form stabl shape devic requir post approv studi condit fda issu updat safeti silicon gel-fil breast implant includ allergan/mentor post-approv data allergan mentor submit pma silicon gel-fil breast implant fda approv high-strength cohes gel fill devic textur surfac sientraallerganmentoropusnatrel contracturereoperationcomplicationfollow-up esta
breast implant market divid two main segment aesthet breast
reconstruct post-mastectomi procedur establish lab focus
thu far primarili aesthet segment size market depend level
measur differ price distributor surgeon directli
price also vari end market global breast
augment procedur year
chart breast augment procedur countri
differ price distributor surgeon directli market
also differ price make market difficult size sell price motiva
rang certain distribut latin american market approach
direct european market averag sell price yield market outsid
us us market procedur year
higher per implant market us current
page
pleas see import disclosur inform page report
nameprocedur world-wid totalunit esta
unit state market domin mentor johnson johnson
natrel allergan remaind market belong intern
two larger player compet extens well broader group
competitor bellagel han biom cerepla silim arion laboratori
sell outsid us allud plan go oversea major
compani oper number busi either broader aesthet
materi manufactur implant innov focu
chart particip estim us market share
page
pleas see import disclosur inform page report
mani player intern competitor oper without
vigor fda approv process compani
maker approv silicone-bas implant ce mark europ approv
countri mentor allergan avail nearli everi market
intern market one small number local smaller player
isap jefferi estim journal aesthet surgeri compani inform
note industri remain rel bereft innov awar
major advanc underway implant compani moreov competitor
would want bring new implant enhanc featur market would
embark multi-year process design anim studi intern studi fda
clinic trial commerci
littl chang breast implant technolog past two three decad
establish lab taken advantag opportun innov aspect
implant procedur
among differenti featur new silicon shell truemonobloc new silicon
gel result new shape ergonomix new implant surfac
silksurface/smoothsilk new safeti featur insid bluseal barrier
aspect implant design improv clinic aesthet
truemonobloc high-perform shell stem combin use
silicon chemistri esta proprietari manufactur process technolog allow
compon tightli bond yield high elast properti ductil
shell also includ bluseal technolog proprietari color low-perm
layer shell give visual indic shell integr allow check
implant implant avoid post-implant shell ruptur gel bleed
mix highli purifi biocompat gel viscou elast
properti allow implant act close natur breast
movement appear feel silicon gel proprietari intern
manufactur design implant allow implant fill reduc
page
pleas see import disclosur inform page report
risk creas shell creat ruptur addit gel allow
dynam movement implant result natur appear
chart motiva ergonomix natur dynam movement
motiva implant offer believ better balanc textur
adhes smooth nano-surfac surfac optim biocompat
cell adhes reduc incid capsular contractur langer lab
massachusett institut technolog mit conduct studi mice implant
silksurfac smooth tini implant conclud silksurfac amelior
fibrosi less scar connect tissu decreas fibrosis-depend innat
 insid implant embed rfid micro-transpond current allow
non-invas read serial lot number implant enhanc product safeti
microtranspond code identifi product surgeri
perform surgeon patient creat account motivaimagin
app websit regist implant allow surgeon access patient
inform chip moment capabl limit implant track
there path develop technolog detect temperatur use
acoust signal detect ruptur uniqu featur manufactur
page
pleas see import disclosur inform page report
clinic data earli encourag
real valu innov establish lab seen clinic perform
motiva implantsand far data better anyth seen breast
compani gener three main piec clinic data date motiva
retrospect studi implant publish sforza et al
publish aesthet surgeri journal septemb
post-market registri implant
on-going prospect follow-up clinic evalu patient
three shown low complic reoper rate outcom
superior publish data competit implant
data uk show minim complic reoper rate sforza et al
conduct retrospect studi evalu complic reoper rate
perform surgeon dolan park hospit uk april april
includ two surfac silksurfac nanotextur
velvetsurfac micro-textur wide rang implant volum two third
particip volum cc
chart particip implant volum categori surfac type
sforza md et al evalu experi silksurfac
trial show posit outcom complic identifi
follow-up period frequent complic infect case
earli seroma predomin implant replac case
ruptur due metal injuri devic ruptur count devic
page
pleas see import disclosur inform page report
failur furthermor case late seroma persist swell breast pain
rippl redness/rash capsular contractur primari case interestingli overal
complic rate significantli lower silksurfac implant
velvetsurfac theoret due benefit nanotextur micro-
sforza md et al evalu experi silksurfac velvetsurfac motiva silicon breast implant aesthet
trial also includ anecdot analysi surgeon period prior
shift motiva period overal revis rate group
util differ macro-textur fda approv implant
treatment protocol order magnitud higher
rate report motiva importantli surgeon util aftercar
system entir seven year span two differ implant
chart motiva patient less like requir revis oper
sforza md et al evalu experi silksurfac
on-going prospect studi also posit esta also
conduct prospect follow-up clinic safeti effect evalu
motiva augment revis patient safeti assess
complic reoper rate efficaci evalu level
satisfact surgeon patient qualiti life interim result
patient four year patient analyz year seven show report implant
ruptur capsular contractur advers event-rel reoper patient
seven year reoper reoper size chang
none due safeti issu
registri show ruptur capsular contractur reoper
compani also keep intern registri implant past seven year
record less ruptur capsular contractur reoper rate
implant see competit comparison
page
pleas see import disclosur inform page report
implant surfacesilkvelvetsilkvelvetsilkvelvetsilkvelvetnumb augmentationimpl replacementprimari mastopexi mastopexi implant competitor esta
chart prospect clinic evalu port-market vigil data show
low complic reoper rate
although posit data present somewhat limit earli come
experi center despit limit howev esta data
suggest implant perform much better clinic
implant market
competit clinic data much less compel
compar data differ studi difficult method challeng
comparison earli data motiva track record establish player
inform esta sever competitor global focu implant
mentor allergan data implant come
compani fda clinic trial
note clinic data breast implant even fda core studi
consist report compani avail fda
moreov comparison also confound signific number variabl
whether procedur primari augment reconstruct surgic
approach implant placement site techniqu irrig pocket use
sleev implant aggreg data analysi look primarili
publish studi fda studi
chart competitor data follow-up
chart competitor data follow-up
data show tabl headlin data current implant suggest
room signific improv capsular contract rate six year rang
reoper rang year
reoper due cosmet reason big proport due clinic
page
pleas see import disclosur inform page report
